tirzepatide medication names Mounjaro (tirzepatide): Uses, Side Effects, Dosage & More Tirzepatide - Wikipedia

How does TRIPLE G differ from dual GIP/GLP-1 agonists

Fernndez-Checa

This eating approach also accounts for the fact that appetite suppression can lead to nutritional gaps

| Medication | Receptor Targets | Peak Weight Loss (Trials) | Wyoming 503A Access | |---|---|---|---| | Semaglutide 2.4 mg | GLP-1 | 14.9% at 68 wk (STEP-1) [2] | Yes | | Tirzepatide 15 mg | GIP + GLP-1 | 20.9% at 72 wk (SURMOUNT-1) [3] | Yes | | Retatrutide 12 mg | GIP + GLP-1 + Glucagon | 24.2% at 48 wk (Phase 2) [1] | Yes | The 24.2% result for retatrutide came at 48 weeks, a shorter trial duration than STEP-1 (68 weeks) or SURMOUNT-1 (72 weeks)

Use half as much by volume for the same dose